Tags |
|
|
Links |
|
|
Actual - Excessive Credit Card Debt
Most people advocate the case of credit cards, quoting the benefits and convenience that arises from them. However, there is another group/line-of-th
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ought that strongly opposes credit cards. The reason being ‘Excessive Credit Card Debt’, which is one of the most serious problems faced by the credi
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
t card holders and credit card industry. However, you can’t pull the shutters on the credit card industry just because of a few irresponsible people
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
(or even if it’s more than few). That is not a solution for beating excessive credit card debt. Moreover, you can’t overlook the benefits associated
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
with the credit cards.
The issue of excessive credit card debt can be looked at from 2 angles. First is addressing of the excessive credit card debt
The issue of excessive credit card debt can be looked at from 2 angles. First is addressing of the excessive credit card debt
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
problem at the industry level and second is the addressing of the excessive credit card debt problem at the individual’s level i.e. at the credit car
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
d holder level. The first method involves increasing awareness of the excessive credit card debt problem to the masses. This is more or less being do
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ne currently too. However, there should also be an effort to tackle this problem of excessive credit card debt at an even deeper level. This means tr
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ying to devise a mechanism to nip the problem (of excessive credit card debt) in the bud. This mechanism should actually be a part of the overall sys
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
tem. A lot of thought needs to go into devising such a mechanism. Case studies should be taken up, statistics gathered and a proper forum formed (wit
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
representatives from the credit card holders and from the credit card suppliers). As of now, the credit card suppliers just seem to be engaged in co
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
ming out with new products and getting customers enrolled to those products. There is little attention paid towards addressing the problem of excessi
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
ve credit card debt in the real sense. Something like attending mandatory seminars on the root causes of excessive credit card debt could be made par
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
t of the credit card application process.
Another way of dealing with the problem of excessive credit card debt could be: developing a system for ca
Another way of dealing with the problem of excessive credit card debt could be: developing a system for ca
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
lculation of applicable credit card limit at the individual level i.e. no standard/product-based credit limits. Then there could be mechanisms for pr
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
actively warning the users about excessive credit card debt (based on their credit card usage) or even imposition of early restrictions on noticing t
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
he first signs that lead to excessive credit card debt.
At the individual’s level, the treatment of the problem of excessive credit card debt would
At the individual’s level, the treatment of the problem of excessive credit card debt would
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
include following of best practices (on credit card usage and avoidance of excessive credit card debt) by the individuals themselves. A checklist or
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
a set of questions could be provided to individuals for recognising the first signs of excessive credit card debt.
So, the problem of excessive cred
So, the problem of excessive cred
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
it card debt can surely be dealt with by putting together some serious thinking at a broader level together with discipline at the individual’s level
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.actual.org.ua/article/99151/actual-Excessive-Credit-Card-Debt.html">Excessive Credit Card Debt</a>
BB link (for phorums):
[url=http://www.actual.org.ua/article/99151/actual-Excessive-Credit-Card-Debt.html]Excessive Credit Card Debt[/url]
Related Articles:
The CEO is 10,000 Feet Above the Fire
Prescription for Success: The Role of the Pharmacy Call in Pharmaceutical Sales
Bookmark it:
|